A Study of a New Vaccine Against Two Types of Ebola

A Phase I Study to Determine the Safety and Immunogenicity of a Bivalent ChAdOx1 Vectored Vaccine Against Zaire and Sudan Ebola Virus Species in UK Healthy Adult Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05079750

Enrollment

Registered

2021-10-15

Start date

2021-11-11

Completion date

2023-03-21

Last updated

2025-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ebola

Keywords

Ebola Virus Disease, Zaire Ebolavirus, EBOV, Sudan Ebolavirus, SUDV, Vaccine

Brief summary

An open-label, non-randomised, dose escalation, first-in-human, single centre, phase I clinical trial to determine the safety and immunogenicity of a bivalent ChAdOx1 vectored vaccine against Zaire and Sudan Ebola virus species in healthy adult volunteers.

Detailed description

This is a first-in-human, open-label, dose escalation, phase I clinical trial to assess the safety and immunogenicity of the candidate ChAdOx1 biEBOV vaccine in healthy UK volunteers aged 18-55. The vaccine will be administered intramuscularly (IM). Volunteers will be recruited and vaccinated at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford. There will be 3 study groups and it is anticipated that a total of 26 volunteers will be enrolled. Dose escalation and sentinel participant procedures will be implemented. Volunteers will be first recruited into Group 1 and subsequently into Groups 2 and 3 following interim clinical safety reviews. Volunteers will be sequentially allocated to a study group by selecting eligible volunteers for enrolment following screening. Sequential allocation will occur based on the order in which volunteers are enrolled.

Interventions

BIOLOGICALChAdOx1 biEBOV

ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

1. Healthy adults aged 18 to 55 years. 2. Able and willing (in the Investigator's opinion) to comply with all study requirements. 3. Willing to allow confirmation of their past medical history either through: provision of a GP medical record summary, allowing investigators to obtain a copy of their medical history from their GP practice or by providing an alternative acceptable means of confirming their past medical history. 4. Agreement to refrain from blood donation during the course of the study. 5. Provide written informed consent. 6. For women of childbearing potential only: Willingness to practice continuous effective contraception for the duration of the trial. 7. For women of childbearing potential only: A negative pregnancy test on the day of both screening and vaccination.

Exclusion criteria

1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment or during the trial follow up period. 2. Receipt of a recombinant simian adenoviral vaccine prior to enrolment. 3. Planned receipt of another adenoviral vectored vaccine (e.g. Oxford/AstraZeneca or Janssen COVID-19 vaccines) within 90 days after the vaccination with the ChAdOx1 biEBOV. 4. Planned or actual receipt of any vaccines administered within 30 days (before or after) enrolment and/or planned receipt of a vaccine ≤30 days after enrolment EXCEPT for protein, RNA (or other non-adenovirus based) COVID-19 vaccinations which may be given within 14 days of the trial vaccine. 5. Previous receipt of an Ebolavirus vaccine. 6. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate. 7. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) systemically active immunosuppressant medication within the past 6 months. 8. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Including hypersensitivity to the active substance or to any of the excipients of the IMP or Vaxzevria (i.e. the Oxford/AstraZeneca COVID-19 vaccine). 9. History of hereditary angioedema, acquired angioedema, or idiopathic angioedema. 10. History of anaphylaxis in relation to vaccination. 11. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). 12. History of serious psychiatric condition likely to affect participation in the study. 13. Ongoing or planned pregnancy or breastfeeding during the trial follow up period. 14. Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture. 15. History of confirmed major thrombotic event (including cerebral venous sinus thrombosis, deep vein thrombosis, pulmonary embolism), history of antiphospholipid syndrome, or history of heparin induced thrombocytopenia. 16. Individuals who have experienced thrombosis with thrombocytopenia syndrome (TTS) following vaccination with Vaxzevria (i.e. the Oxford/AstraZeneca COVID-19 vaccine). 17. Individuals who have previously experienced episodes of capillary leak syndrome. 18. Any other serious chronic illness requiring hospital specialist supervision. 19. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week. 20. Suspected or known injecting drug abuse in the 5 years preceding enrolment. 21. Detectable circulating hepatitis B surface antigen (HBsAg). 22. Seropositive for hepatitis C virus (antibodies to HCV). 23. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis. 24. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.

Design outcomes

Primary

Measure	Time frame	Description
Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	7 days following vaccination	Occurrence of solicited local and systemic reactogenicity signs and symptoms. Data shown are number (and percentage) of participants reporting each event. The maximum severity of any local and any systemic solicited symptoms reported by individual participants is also shown.
Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	28 days following vaccination	Occurrence of unsolicited adverse events (AEs)
Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Serious Adverse Events	Duration of the study (6 months)	Occurrence of serious adverse events (SAEs) and adverse interests of special interest (AESIs)
Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	28 days following vaccination	Abnormal results were graded according to a pre-specified laboratory adverse events severity grading scale - a full breakdown of the levels of severity of the reported events per study timepoint is available in the publication.

Secondary

Measure	Time frame	Description
Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Humoral Immunogenicity	At day 28	ELISA to quantify antibodies to filovirus glycoprotein (specific serological response). Peak antibody responses to both Ebola and Sudan viruses occurred 28 days post vaccination (or post-boost, in the participants who received a booster) across all groups.
Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Cellular Immunogenicity	14 days post final vaccine for each group	Intracellular cytokine staining (ICS) by flow cytometry was carried out at baseline as well as at 14 days after vaccination/boost to assess T-cell responses to Ebola virus glycoprotein and Sudan virus glycoprotein.

Countries

United Kingdom

Participant flow

Participants by arm

Arm	Count
Group 1: Low Dose n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 5x10\^9 vp ChAdOx1 biEBOV: ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)	6
Group 2: Mid Dose n=6 participants vaccinated with a single dose of ChAdOx1 biEBOV 2.5x10\^10 vp ChAdOx1 biEBOV: ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)	6
Group 3: High Dose - Single Dose n=7 participants vaccinated with a single dose of ChAdOx1 biEBOV 5x10\^10 vp ChAdOx1 biEBOV: ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)	7
Group 3: High Dose - Two Doses n=7 participants vaccinated with two doses twelve weeks apart of ChAdOx1 biEBOV 5x10\^10 vp ChAdOx1 biEBOV: ChAdOx1 biEBOV provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)	7
Total	26

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002
Overall Study	Lost to Follow-up	0	0	1

Baseline characteristics

Characteristic	Group 1: Low Dose	Group 2: Mid Dose	Group 3: High Dose - Single Dose	Group 3: High Dose - Two Doses	Total
Age, Customized	24 years	26 years	20 years	30 years	28 years
Race/Ethnicity, Customized Asian or Asian British	0 Participants	0 Participants	2 Participants	0 Participants	2 Participants
Race/Ethnicity, Customized Black Carribean and Mixed White or	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Other Asian Background	0 Participants	1 Participants	1 Participants	0 Participants	2 Participants
Race/Ethnicity, Customized White	6 Participants	4 Participants	4 Participants	7 Participants	21 Participants
Region of Enrollment United Kingdom	6 Participants	6 Participants	7 Participants	7 Participants	26 Participants
Sex: Female, Male Female	4 Participants	3 Participants	5 Participants	4 Participants	16 Participants
Sex: Female, Male Male	2 Participants	3 Participants	2 Participants	3 Participants	10 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	0 / 6	0 / 6	0 / 14	0 / 7
other Total, other adverse events	6 / 6	5 / 6	12 / 14	5 / 7
serious Total, serious adverse events	1 / 6	0 / 6	0 / 14	0 / 7

Outcome results

Primary

Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities

Abnormal results were graded according to a pre-specified laboratory adverse events severity grading scale - a full breakdown of the levels of severity of the reported events per study timepoint is available in the publication.

Time frame: 28 days following vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alanine transaminase	Normal	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	White blood cell count	Normal	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Urea	Abnormal	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alkaline phosphatase	Normal	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Lymphocyte count	Normal	5 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Eosinophil count	Normal	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Eosinophil count	Abnormal	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Urea	Normal	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Hemoglobin	Abnormal	1 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Hemoglobin	Normal	5 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alkaline phosphatase	Abnormal	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Platelet count	Abnormal	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Bilirubin	Normal	5 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	White blood cell count	Abnormal	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Bilirubin	Abnormal	1 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Albumin	Normal	5 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Platelet count	Normal	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Creatinine	Normal	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Creatinine	Abnormal	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Neutrophil count	Abnormal	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Potassium	Normal	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Potassium	Abnormal	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Albumin	Abnormal	1 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Neutrophil count	Normal	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Sodium	Normal	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Sodium	Abnormal	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alanine transaminase	Abnormal	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Lymphocyte count	Abnormal	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	White blood cell count	Normal	5 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Urea	Normal	6 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Bilirubin	Abnormal	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Lymphocyte count	Normal	4 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Neutrophil count	Normal	4 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Urea	Abnormal	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Sodium	Normal	6 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Potassium	Abnormal	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Creatinine	Normal	6 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Eosinophil count	Normal	6 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alkaline phosphatase	Normal	6 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Hemoglobin	Abnormal	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Albumin	Normal	6 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Eosinophil count	Abnormal	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Neutrophil count	Abnormal	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Albumin	Abnormal	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Creatinine	Abnormal	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Hemoglobin	Normal	6 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alanine transaminase	Abnormal	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Platelet count	Abnormal	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	White blood cell count	Abnormal	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alkaline phosphatase	Abnormal	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alanine transaminase	Normal	5 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Lymphocyte count	Abnormal	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Sodium	Abnormal	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Bilirubin	Normal	5 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Potassium	Normal	6 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Platelet count	Normal	6 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Eosinophil count	Abnormal	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alanine transaminase	Normal	14 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alanine transaminase	Abnormal	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Albumin	Normal	14 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Albumin	Abnormal	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alkaline phosphatase	Normal	14 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alkaline phosphatase	Abnormal	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Bilirubin	Normal	10 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Bilirubin	Abnormal	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Creatinine	Normal	14 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Creatinine	Abnormal	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Potassium	Normal	10 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Potassium	Abnormal	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Sodium	Normal	14 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Sodium	Abnormal	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Urea	Normal	14 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Urea	Abnormal	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Eosinophil count	Normal	14 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Hemoglobin	Normal	12 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Hemoglobin	Abnormal	2 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Lymphocyte count	Normal	6 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Lymphocyte count	Abnormal	8 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Neutrophil count	Normal	9 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Neutrophil count	Abnormal	5 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Platelet count	Normal	13 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Platelet count	Abnormal	1 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	White blood cell count	Normal	14 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	White blood cell count	Abnormal	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Sodium	Abnormal	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Sodium	Normal	7 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Albumin	Normal	7 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Lymphocyte count	Abnormal	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Potassium	Abnormal	2 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Potassium	Normal	5 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	White blood cell count	Abnormal	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Neutrophil count	Normal	5 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Creatinine	Abnormal	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Creatinine	Normal	7 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	White blood cell count	Normal	7 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Neutrophil count	Abnormal	2 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Bilirubin	Abnormal	2 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Bilirubin	Normal	5 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alanine transaminase	Abnormal	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Platelet count	Normal	6 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alkaline phosphatase	Abnormal	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alkaline phosphatase	Normal	7 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Alanine transaminase	Normal	7 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Hemoglobin	Normal	7 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Eosinophil count	Abnormal	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Eosinophil count	Normal	7 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Platelet count	Abnormal	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Hemoglobin	Abnormal	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Urea	Abnormal	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Urea	Normal	7 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Albumin	Abnormal	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities	Lymphocyte count	Normal	7 Participants

Primary

Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Serious Adverse Events

Occurrence of serious adverse events (SAEs) and adverse interests of special interest (AESIs)

Time frame: Duration of the study (6 months)

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Serious Adverse Events	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Serious Adverse Events	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Serious Adverse Events	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Serious Adverse Events	0 Participants

Primary

Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms

Occurrence of solicited local and systemic reactogenicity signs and symptoms. Data shown are number (and percentage) of participants reporting each event. The maximum severity of any local and any systemic solicited symptoms reported by individual participants is also shown.

Time frame: 7 days following vaccination

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Moderate	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Did not report this event	3 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Mild	3 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Moderate	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Did not report this event	3 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Mild	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Moderate	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Did not report this event	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Mild	1 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Moderate	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Mild	3 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Did not report this event	5 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Mild	2 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Moderate	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Did not report this event	4 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Mild	3 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Moderate	3 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Did not report this event	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Mild	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Moderate	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Did not report this event	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Mild	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Moderate	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Did not report this event	6 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Mild	3 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Moderate	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Did not report this event	3 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Mild	1 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Moderate	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Did not report this event	5 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Mild	1 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Moderate	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Did not report this event	5 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Mild	2 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Moderate	2 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Did not report this event	2 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Mild	2 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Moderate	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Did not report this event	4 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Mild	3 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Moderate	1 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Severe	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Did not report this event	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Mild	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Moderate	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Mild	3 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Moderate	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Moderate	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Did not report this event	4 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Moderate	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Moderate	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Mild	3 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Mild	3 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Mild	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Did not report this event	4 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Mild	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Did not report this event	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Mild	3 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Mild	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Mild	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Moderate	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Did not report this event	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Moderate	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Did not report this event	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Moderate	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Did not report this event	5 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Mild	4 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Did not report this event	5 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Moderate	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Did not report this event	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Moderate	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Moderate	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Did not report this event	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Moderate	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Did not report this event	4 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Did not report this event	5 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Mild	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Did not report this event	6 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Mild	4 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Mild	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Moderate	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Did not report this event	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Mild	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Moderate	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Did not report this event	6 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Severe	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Mild	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Did not report this event	14 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Moderate	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Mild	2 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Moderate	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Did not report this event	12 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Mild	2 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Moderate	10 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Did not report this event	3 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Did not report this event	2 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Did not report this event	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Moderate	5 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Moderate	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Mild	6 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Did not report this event	14 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Mild	6 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Moderate	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Moderate	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Did not report this event	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Mild	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Moderate	1 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Did not report this event	9 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Mild	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Moderate	6 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Did not report this event	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Did not report this event	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Mild	1 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Moderate	3 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Mild	6 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Mild	9 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Moderate	1 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Did not report this event	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Mild	9 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Moderate	1 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Did not report this event	10 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Did not report this event	4 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Mild	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Moderate	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Mild	6 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Severe	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Did not report this event	14 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Mild	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Moderate	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Moderate	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Mild	2 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Moderate	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Mild	4 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Did not report this event	6 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Mild	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Mild	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Moderate	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Moderate	3 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Moderate	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any local symptom	Did not report this event	2 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Mild	3 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fever	Mild	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Mild	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Mild	4 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Did not report this event	2 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Did not report this event	4 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Moderate	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Moderate	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Did not report this event	7 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Did not report this event	6 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Moderate	3 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Mild	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Did not report this event	6 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Pain	Did not report this event	2 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Mild	3 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Moderate	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Any systemic symptom	Mild	2 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Moderate	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Moderate	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Nausea	Mild	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Itch	Did not report this event	7 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Did not report this event	6 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Did not report this event	5 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Redness	Mild	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Malaise	Did not report this event	3 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Headache	Did not report this event	3 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Feverishness	Moderate	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Warmth	Did not report this event	6 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Mild	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Myalgia	Moderate	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Fatigue	Severe	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms	Arthralgia	Moderate	0 Participants

Primary

Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms

Occurrence of unsolicited adverse events (AEs)

Time frame: 28 days following vaccination

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Infections and infestations (vaccine-related)	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Gastrointestinal disorders (vaccine-related)	1 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	General disorders and administration site reactions (vaccine-related)	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Musculoskeletal and connective tissue disorders (vaccine-related)	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Cardiac disorders (vaccine-related)	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Nervous system disorders (vaccine-related)	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Reproductive system and breast disorders (vaccine-related)	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Respiratory, thoracic and mediastinal disorders (vaccine-related)	2 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Cardiac disorders (vaccine-unrelated)	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Gastrointestinal disorders (vaccine-unrelated)	3 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	General disorders and administration site reactions (vaccine-unrelated)	3 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Musculoskeletal and connective tissue disorders (vaccine-unrelated)	1 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Infections and infestations (vaccine-unrelated)	0 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Nervous system disorders (vaccine-unrelated)	1 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Reproductive system and breast disorders (vaccine-unrelated)	1 Participants
Group 1: Low Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Respiratory, thoracic and mediastinal disorders (vaccine-unrelated)	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Nervous system disorders (vaccine-related)	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Cardiac disorders (vaccine-unrelated)	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Respiratory, thoracic and mediastinal disorders (vaccine-unrelated)	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Musculoskeletal and connective tissue disorders (vaccine-unrelated)	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Reproductive system and breast disorders (vaccine-unrelated)	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Gastrointestinal disorders (vaccine-unrelated)	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	General disorders and administration site reactions (vaccine-related)	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	General disorders and administration site reactions (vaccine-unrelated)	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Infections and infestations (vaccine-related)	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Reproductive system and breast disorders (vaccine-related)	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Musculoskeletal and connective tissue disorders (vaccine-related)	0 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Gastrointestinal disorders (vaccine-related)	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Infections and infestations (vaccine-unrelated)	1 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Respiratory, thoracic and mediastinal disorders (vaccine-related)	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Nervous system disorders (vaccine-unrelated)	2 Participants
Group 2: Mid Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Cardiac disorders (vaccine-related)	2 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Nervous system disorders (vaccine-related)	3 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Infections and infestations (vaccine-related)	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Nervous system disorders (vaccine-unrelated)	3 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Reproductive system and breast disorders (vaccine-related)	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Respiratory, thoracic and mediastinal disorders (vaccine-related)	1 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Respiratory, thoracic and mediastinal disorders (vaccine-unrelated)	5 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Cardiac disorders (vaccine-unrelated)	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Gastrointestinal disorders (vaccine-unrelated)	1 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Reproductive system and breast disorders (vaccine-unrelated)	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	General disorders and administration site reactions (vaccine-unrelated)	3 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Musculoskeletal and connective tissue disorders (vaccine-unrelated)	1 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Cardiac disorders (vaccine-related)	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Gastrointestinal disorders (vaccine-related)	1 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Infections and infestations (vaccine-unrelated)	0 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	General disorders and administration site reactions (vaccine-related)	2 Participants
Group 3: High Dose - Single Dose	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Musculoskeletal and connective tissue disorders (vaccine-related)	3 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Respiratory, thoracic and mediastinal disorders (vaccine-unrelated)	4 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Respiratory, thoracic and mediastinal disorders (vaccine-related)	2 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	General disorders and administration site reactions (vaccine-related)	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Cardiac disorders (vaccine-related)	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Nervous system disorders (vaccine-unrelated)	3 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Reproductive system and breast disorders (vaccine-related)	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Infections and infestations (vaccine-unrelated)	3 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Gastrointestinal disorders (vaccine-related)	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Infections and infestations (vaccine-related)	1 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Gastrointestinal disorders (vaccine-unrelated)	3 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Nervous system disorders (vaccine-related)	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	General disorders and administration site reactions (vaccine-unrelated)	2 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Reproductive system and breast disorders (vaccine-unrelated)	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Cardiac disorders (vaccine-unrelated)	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Musculoskeletal and connective tissue disorders (vaccine-related)	0 Participants
Group 3: High Dose - Two Doses	Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms	Musculoskeletal and connective tissue disorders (vaccine-unrelated)	0 Participants

Secondary

Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Cellular Immunogenicity

Intracellular cytokine staining (ICS) by flow cytometry was carried out at baseline as well as at 14 days after vaccination/boost to assess T-cell responses to Ebola virus glycoprotein and Sudan virus glycoprotein.

Time frame: 14 days post final vaccine for each group

Arm	Measure	Group	Value (MEDIAN)
Group 1: Low Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Cellular Immunogenicity	Antigen-specific CD8+ T cells to EBOV	0.0300 frequency (proportion of parent cells)
Group 1: Low Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Cellular Immunogenicity	Antigen-specific CD8+ T cells to SUDV	0.0320 frequency (proportion of parent cells)
Group 2: Mid Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Cellular Immunogenicity	Antigen-specific CD8+ T cells to SUDV	0.0340 frequency (proportion of parent cells)
Group 2: Mid Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Cellular Immunogenicity	Antigen-specific CD8+ T cells to EBOV	0.0000 frequency (proportion of parent cells)
Group 3: High Dose - Single Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Cellular Immunogenicity	Antigen-specific CD8+ T cells to EBOV	0.0850 frequency (proportion of parent cells)
Group 3: High Dose - Single Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Cellular Immunogenicity	Antigen-specific CD8+ T cells to SUDV	0.1120 frequency (proportion of parent cells)
Group 3: High Dose - Two Doses	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Cellular Immunogenicity	Antigen-specific CD8+ T cells to EBOV	0.1190 frequency (proportion of parent cells)
Group 3: High Dose - Two Doses	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Cellular Immunogenicity	Antigen-specific CD8+ T cells to SUDV	0.0485 frequency (proportion of parent cells)

Secondary

Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Humoral Immunogenicity

ELISA to quantify antibodies to filovirus glycoprotein (specific serological response). Peak antibody responses to both Ebola and Sudan viruses occurred 28 days post vaccination (or post-boost, in the participants who received a booster) across all groups.

Time frame: At day 28

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Group 1: Low Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Humoral Immunogenicity	Peak anti-EBOV antibody titers (occurred at D28)	63.3 ELISA units
Group 1: Low Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Humoral Immunogenicity	Peak anti-SUDV antibody titers (occurred at D28)	27.0 ELISA units
Group 2: Mid Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Humoral Immunogenicity	Peak anti-SUDV antibody titers (occurred at D28)	101.7 ELISA units
Group 2: Mid Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Humoral Immunogenicity	Peak anti-EBOV antibody titers (occurred at D28)	164.2 ELISA units
Group 3: High Dose - Single Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Humoral Immunogenicity	Peak anti-EBOV antibody titers (occurred at D28)	260.1 ELISA units
Group 3: High Dose - Single Dose	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Humoral Immunogenicity	Peak anti-SUDV antibody titers (occurred at D28)	111.5 ELISA units
Group 3: High Dose - Two Doses	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Humoral Immunogenicity	Peak anti-EBOV antibody titers (occurred at D28)	1169.7 ELISA units
Group 3: High Dose - Two Doses	Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Humoral Immunogenicity	Peak anti-SUDV antibody titers (occurred at D28)	568.0 ELISA units

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026

A Study of a New Vaccine Against Two Types of Ebola

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Clinical Laboratory Abnormalities

Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Serious Adverse Events

Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms

Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Unsolicited Signs and Symptoms

Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Cellular Immunogenicity

Immunogenicity of ChAdOx1 biEBOV in Healthy Adult Volunteers: Measure of Humoral Immunogenicity